Teladoc Health, Inc. (TDOC) AI Stock Analysis

Teladoc Health, Inc. is a provider of virtual healthcare services catering to a global clientele across the United States and internationally. Founded in 2002 and based in Purchase, New York, the company offers telehealth programs and services ranging from primary and specialty care to chronic condition management and mental health therapies. Its solutions address medical needs such as diabetes, hypertension, chronic kidney disease, cancer, and congestive heart failure. Teladoc Health serves employers, health plans, hospitals, health systems, insurance companies, financial services firms, and individual members.

Teladoc Health delivered annual revenue growth of 85.8% in FY2021 to $2.03B, followed by 18.4% growth to $2.41B in FY2022 and 8.1% growth to $2.60B in FY2023. Top-line revenue subsequently fell 1.3% to $2.57B in FY2024 and declined 1.5% to $2.53B in FY2025. Over the trailing twelve months ended June 30, 2026, revenue stood at $2.49B, with quarterly revenue growth declining 4.0% year-over-year. Net income was -$428.8M in FY2021, -$13.66B in FY2022, -$220.4M in FY2023, -$1.00B in FY2024, and -$200.3M in FY2025, reflecting an operating margin of -10.4% in FY2025 and a trailing twelve-month operating margin of -5.7%.

As of June 30, 2026, Teladoc Health held $774.3M in cash and short-term investments alongside total debt of $1.04B, resulting in net debt of $261.9M. Shareholders' equity was $1.31B, with total assets of $2.76B, a current ratio of 0.83, and a debt-to-equity ratio of 0.79. During FY2025, the company generated $294.4M in operating cash flow and $285.5M in free cash flow, while spending $8.9M on capital expenditures. Its share count increased 12.6% over 5 years.

Teladoc Health closed at $5.67 on October 16, 2026, giving it an enterprise value of $1.42B. The stock trades at a price-to-sales multiple of 0.4x, below the median of its US-listed Healthcare peers of 4.1x. Its enterprise value to EBITDA ratio of 6.6x also sits below the peer median of 12.0x, while its forward price-to-earnings ratio is 303.0x compared to the peer median of 17.3x. Over the past year, the shares dropped 37.1% compared to a 16.8% return for the S&P 500, and fell 95.8% over five years versus an 83.0% gain for the index.

Wall Street sentiment includes 5 Strong Buy, 1 Buy, and 17 Hold ratings, with 0 Sell or Strong Sell recommendations. The mean price target is $7.59, representing a 33.8% premium over the last close of $5.67. For the fiscal year ending December 31, 2026, analysts estimate revenue of $2.42B and an EPS of -$0.79. Teladoc Health beat EPS estimates in each of the last 4 quarters, with its next earnings date scheduled for October 28, 2026.

This page is an AI-written research summary of Teladoc Health, Inc. (TDOC). The text was generated on October 30, 2026 from Quotelinks data as of October 16, 2026 (company profile, annual results, latest balance sheet, valuation, price performance and analyst estimates). An automatic check rejects any draft that contains a figure not found in that data. It is not investment advice; verify figures on the linked tabs before making decisions.

Related: TDOC income statement, TDOC balance sheet, TDOC key metrics, TDOC analyst forecast, TDOC chart. See the TDOC stock overview for the latest quote and news.